These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7417037)

  • 21. Gel-filtration on psoriasic and uremic serum and dialysis fluid.
    Lamperi S; Buoncristiani U; Carozzi S; Cozzari M; Icardi A; Trasforini D
    Artif Organs; 1981; 4 Suppl():156-9. PubMed ID: 7295083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemical analytic approaches to the definition of uremic toxins.
    Furst P; Bergstrom J; Gordon A; Zimmermann L
    Ateneo Parmense Acta Biomed; 1975; 46(5):307-16. PubMed ID: 1232992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Uremic toxin and dialysis].
    Kobayashi K; Maeda K; Kawaguchi S
    Nihon Jinzo Gakkai Shi; 1976 Jun; 18(6):412-4. PubMed ID: 988343
    [No Abstract]   [Full Text] [Related]  

  • 24. ["Middle molecules" as nonspecific regulators of phagocyte activity].
    Volchegorskiĭ IA; Vlasov AV; Livshits GE; Akhkiamov EM; Skobeleva NA; Lifshits RI; Ebert LIa
    Biull Eksp Biol Med; 1995 Feb; 119(2):159-62. PubMed ID: 7670039
    [No Abstract]   [Full Text] [Related]  

  • 25. Hippuric acid as a marker.
    Vanholder R; Schoots A; Cramers C; De Smet R; Van Landschoot N; Wizemann V; Botella J; Ringoir S
    Adv Exp Med Biol; 1987; 223():59-67. PubMed ID: 3447451
    [No Abstract]   [Full Text] [Related]  

  • 26. Serum and ultradiafiltrate middle molecules in hemodialysed patients.
    Bozek P; Erben J; Zahradnik J; Dzúrik R
    Int Urol Nephrol; 1979; 11(3):223-8. PubMed ID: 500299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemofiltration-induced serum modifications in the pattern of larger molecules.
    David S; Barani R; Buzio C; Arisi L; Quaretti P
    Adv Exp Med Biol; 1987; 223():281-6. PubMed ID: 3447447
    [No Abstract]   [Full Text] [Related]  

  • 28. [Biochemical definition of uremia].
    Ringoir S
    Verh K Acad Geneeskd Belg; 1981; 43(2):105-19. PubMed ID: 7314875
    [No Abstract]   [Full Text] [Related]  

  • 29. Chromatographic analysis of middle molecules in plasma ultrafiltrates of uraemic patients.
    Popławski A; Myśliwiec M
    Nephrol Dial Transplant; 1993; 8(2):188. PubMed ID: 8384345
    [No Abstract]   [Full Text] [Related]  

  • 30. Inhibition of platelet function by uremic middle molecules.
    Bazilinski N; Shaykh M; Dunea G; Mamdani B; Patel A; Czapek E; Ahmed S
    Nephron; 1985; 40(4):423-8. PubMed ID: 4022211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The synthesis of middle molecular substances in rat tissues: in vitro study.
    Dzúrik R; Cernácek P; Spustová V; Válek A
    Proc Eur Dial Transplant Assoc; 1978; 15():633-5. PubMed ID: 740703
    [No Abstract]   [Full Text] [Related]  

  • 32. Uremic toxins.
    Ringoir S; Schoots A; Vanholder R
    Kidney Int Suppl; 1988 Mar; 24():S4-9. PubMed ID: 3283412
    [No Abstract]   [Full Text] [Related]  

  • 33. [Middle molecules and the problem of endogenous intoxication in critical states of various etiologies].
    Vladyka AS; Levitskiĭ ER; Poddubnaia LP; Gabriélian NI
    Anesteziol Reanimatol; 1987; (2):37-42. PubMed ID: 3300433
    [No Abstract]   [Full Text] [Related]  

  • 34. Technical aspects on middle molecules: separation, isolation, and identification.
    Cueille G; Man NK; Sausse A; Farges JP; Funck-Brentano JL
    Artif Organs; 1981; 4 Suppl():8-12. PubMed ID: 7295100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mathematical formulation of the dialysis index for middle molecules, D1(MM).
    Milutinovic J; Babb AL; Eschbach JW; Follette WC; Graefe U; Strand MJ; Scribner BH
    Artif Organs; 1978 Feb; 2(1):51-4. PubMed ID: 687021
    [No Abstract]   [Full Text] [Related]  

  • 36. [Diagnostic value of determining middle molecules in the blood plasma in nephrological diseases].
    Gabriélian NI; Dmitriev AA; Kulakov GP; Melikian AM; Shcherbaneva OI
    Klin Med (Mosk); 1981 Oct; 59(10):38-42. PubMed ID: 7311409
    [No Abstract]   [Full Text] [Related]  

  • 37. [Examination of lymphokines in patients with hemodialysis (author's transl)].
    Löcsey L; Kálmán K; Hauck M; Kakuk G
    Allerg Immunol (Leipz); 1979; 25(3):211-7. PubMed ID: 162030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Study of middle molecules with positive reaction to ninhydrin present in uremic and normal blood and their isolation].
    Buzio C; Dall'Aglio PP; Delmonte G; Montagna G; Migone L
    Minerva Nefrol; 1979; 26(1):45-8. PubMed ID: 471320
    [No Abstract]   [Full Text] [Related]  

  • 39. Plasma middle molecules in asymptomatic and "sick" uremic patients.
    Asaba H; Bergström J; Fürst P; Johnson C; Yahiel V
    Artif Organs; 1981; 4 Suppl():137-42. PubMed ID: 7295080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uremic toxins inhibit the platelet malonyldialdehyde production rate.
    Tanaka H; Itoh S; Yamagami S; Kishimoto T; Maekawa M; Ringoir S
    Adv Exp Med Biol; 1987; 223():115-8. PubMed ID: 3447425
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.